Liquidia Technologies Inc (LQDA) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $66.88 (-2.21%), Market cap $5.49B, P/E ratio 363.35, 52-week low–high $12.00 ~ $61.97.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension
Financial statements, price targets, institutional (13F) holdings and related news for Liquidia Technologies Inc are updated in real time on BlackAll Trade.
Liquidia Technologies Inc trades at $66.88 (-2.21%). Real-time quotes and charts are available on BlackAll Trade.
Liquidia Technologies Inc has a market cap of about $5.49B. Its P/E ratio is 363.35.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candid